Last edition
News about "Keytruda Biosimilar "
Zydus to Commercialise Keytruda Biosimilar FYB206 in US and Canada
Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada.
Keytruda Biosimilar | 10/12/2025 | By Darshana | 163
Formycon, MS Pharma Ink MENA Deal for Keytruda Biosimilar FYB206
Formycon has signed an exclusive commercialisation agreement with MS Pharma for its Keytruda biosimilar candidate FYB206 in the MENA region. The deal includes an upfront payment, milestone-based fees, and a significant share of regional gross profits generated in the region.
Keytruda Biosimilar | 05/12/2025 | By Dineshwori | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy